Mol. Hum. Reprod. Advance Access originally published online on December 5, 2005
Molecular Human Reproduction 2005 11(10):711-713; doi:10.1093/molehr/gah211
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Human villous trophoblast and the lack of intron 4-retaining soluble HLA-G secretion: beware of possible methodological biases
INSERM U563, Hôpital Purpan, Toulouse, France
| Introduction |
|---|
|
|
|---|
The straightforward Blaschitz et al. (2005)
| Types of cells |
|---|
|
|
|---|
Besides placental tissue sections, the authors used several cell types to sustain their conclusions. In contrast to previous studies performed on either purified term villous cytotrophoblast (Solier et al., 2002
The choice of control transfectants by the authors may also be a matter of discussion. 221-G5 transfectant is a lymphoblastoid cell line (Ishitani and Geraghty, 1992
). When they compared the diversity of peptide ligands bound to HLA-G expressed by the same transfectant and by trophoblast from term placenta, Ishitani et al. (2003)
discovered that the relative abundance of individual peptides found in .221-HLA-G5 was far lower than that found from the placental-derived cells and that a smaller number of distinct peptides did bind to the placental material. Although this should not alter western blotting analysis, it cannot be excluded that, when using enzyme-linked immunosorbent assay (ELISA), these differences could modify folding of HLA-G and thus affect the affinity of some of the HLA-G monoclonal antibodies (mAb) recognizing conformational determinants.
| Real-time PCR |
|---|
|
|
|---|
Lack of details concerning the standard curves used by the authors (did they use genomic DNA or cDNA? did they make a comparison with a ß-actin standard curve?) and the absence of positive and negative control cell lines render the results rather difficult to evaluate. Other reports, using purified villous cytotrophoblast cells, not only did isolate transcripts encoding HLA-G5 by using RTPCR with intron 4-specific primers, but most importantly, did sequence the corresponding cDNAs, definitely demonstrating they did contain intron 4 (Solier et al., 2002
| Western blotting |
|---|
|
|
|---|
The recombinant HLA-G molecules used as positive control by the authors might not be the most appropriate for this kind of study. Being made in Escherichia coli, this recombinant protein cannot be glycosylated like the soluble HLA-G proteins produced by eukaryote primary trophoblast or trophoblast transfectants. Moreover, the absence of recombinant HLA-G5 control molecule in each western blot experiment does not allow clear comparisons. The reactivity of the MEM-G/1 mAb on 221-HLA-G1 cell-culture supernatant is quite confusing: how a full length membrane-bound HLA-G1 molecule could ever be detected in the cell-culture supernatant? Does this reflect the presence of cells in this supernatant? Could this be due to cell apoptosis, possibly generated by the lack of FCS in the medium? The proofs of the presence of shed HLA-G1 molecules in cell-culture supernatants may also be a subject of discussion. I am not sure that the molecular weight single parameter is enough to assess they are shed forms. It would have been reassuring to demonstrate the appearance of such forms after a specific metalloprotease cleavage. The very low signals obtained in trophoblast culture supernatants make the western blotting data quite difficult to analyse. Immunoprecipitation of culture supernatants with 16G1 mAb followed by MEM-G/1 blotting would have probably help resolving this issue.
| ELISA |
|---|
|
|
|---|
Once again the absence of total purity of the first trimester trophoblast population used by the authors renders the data difficult to evaluate. The time of culture of trophoblast is also an important issue as soluble HLA-G secretion levels measured by ELISA may increase over the time of culture (Solier et al., 2002
| Immunohistochemistry |
|---|
|
|
|---|
The authors showed a strong positive staining of acetone-fixed, cytocentrifuged HLA-G5 transfectants incubated with the 16G1 or 5A6G7 mAbs, both directed against intron-4 peptide, and concluded that the absence of staining of villous cytotrophoblast and syncytiotrophoblast by these mAbs on similarly fixed frozen placental tissue sections, meant that HLA-G5 was not expressed by villous trophoblast in situ. 221-HLA-G5 cells have been transfected with retroviral vectors expressing HLA-G5 cDNA and therefore overexpress the HLA-G5 product, more than 10-fold higher than naturally expressing JEG-3 (Ishitani and Geraghty, 1992
In conclusion, results presented by Blaschitz et al. (2005)
definitely contribute to the discussion as to whether human villous trophoblasts do produce intron 4-retaining soluble HLA-G5 molecules. However, in view of the several possible methodological biases I focused on, their conclusions, summarized in their self-assured manuscript title, perhaps might be considered as premature... I feel that the so-called substantial evidence these authors claim they have provided might need quite a few additional reliable investigations performed on really purified, exclusively villous trophoblast from human placental tissue combined with all of the appropriate controls. Obviously the discussion is not over!
| References |
|---|
|
|
|---|
Astrid Blaschitz, Herbert Juch, Armin Volz, Heinz Hutter, Christine Daxboeck, Gernot Desoye, Gottfried Dohr (2005) The soluble pool of HLA-G produced by human trophoblast does not contain the intron 4-derived peptide. Mol Hum Reprod 00,0000.
Barel M, Ressing M, Pizzato N, van Leeuwen D, Le Bouteiller P, Lenfant F and Wiertz E (2003) Human cytomegalovirus-encoded US2 differentially affects surface expression of MHC class I locus products and targets membrane-bound, but not soluble HLA-G1 for degradation. J Immunol 171,67576765.
Chu W, Fant ME, Geraghty DE and Hunt JS (1998) Soluble HLA-G in human placentas: synthesis in trophoblasts and interferon-gamma-activated macrophages but not placental fibroblasts. Hum Immunol 59,435442.[CrossRef][ISI][Medline]
Ishitani A and Geraghty DE (1992) Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. Proc Natl Acad Sci USA 89,39473951.
Ishitani A, Sageshima N, Lee N, Dorofeeva N, Hatake K, Marquardt H and Geraghty D (2003) Protein expression and peptide binding suggest unique and interacting functional roles for HLA-E, F, and G in maternal-placental immune recognition. J Immunol 171,13761384.
Kohler P and Bridson W (1971) Isolation of hormone-producing clonal lines of human choriocarcinoma. J Clin Endocrinol Metab 32,683687.[ISI][Medline]
Langat DK, Morales PJ, Fazleabas AT, Mwenda JM and Hunt JS (2002) Baboon placentas express soluble and membrane-bound Paan-AG proteins encoded by alternatively spliced transcripts of the class Ib major histocompatibility complex gene, Paan-AG. Immunogenetics 54,164173.[CrossRef][ISI][Medline]
Morales P, Pace J, Platt J, Phillips T, Morgan K, Fazleabas A and Hunt J (2003) Placental cell expression of HLA-G2 isoforms is limited to the invasive trophoblast phenotype. J Immunol 171,62156224.
Ryan AF, Grendell RL, Geraghty DE and Golos TG (2002) A soluble isoform of the rhesus monkey nonclassical MHC class I molecule Mamu-AG is expressed in the placenta and the testis. J Immunol 169,673683.
Slukvin II, Boyson JE, Watkins DI and Golos TG (1998) The rhesus monkey analogue of human lymphocyte antigen-G is expressed primarily in villous syncytiotrophoblasts. Biol Reprod 58,728738.
Solier C, Aguerre-Girr M, Lenfant F, Campan A, Berrebi A, Rebmann V, Grosse-Wilde H and Le Bouteiller P (2002) Secretion of pro-apoptotic intron 4-retaining soluble HLA-G1 by human villous trophoblast. Eur J Immunol 32,35763586[CrossRef][ISI][Medline]
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
A. van der Meer, H.G.M. Lukassen, B. van Cranenbroek, E.H. Weiss, D.D.M. Braat, M.J. van Lierop, and I. Joosten Soluble HLA-G promotes Th1-type cytokine production by cytokine-activated uterine and peripheral natural killer cells Mol. Hum. Reprod., February 1, 2007; 13(2): 123 - 133. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
